All In Biotech

Drug Trial Radar · NCT03450629

Evaluation of Safety and Efficacy of PDP-716

A Randomized, Multi-Center, Investigator-Masked, Parallel Group, Equivalence Study of Once Daily Brimonidine Tartrate Ophthalmic Suspension Compared With Three Times Daily ALPHAGAN-P® in Subjects With Open Angle Glaucoma, or Ocular Hypertension

Last checked: Nov 19, 2026Latest source record: Feb 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 682 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

682

Actual

Start

Sep 13, 2018

Primary completion

Dec 1, 2020

Study completion Dec 1, 2020

Sponsor

Sponsor type
Industry
First posted
Mar 1, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will be conducted to evaluate the efficacy and safety of topical administration of PDP-716 compared with brimonidine tartrate ophthalmic solution.

Conditions

  • Open Angle Glaucoma
  • Ocular Hypertension

Interventions

  • Brimonidine Tartrate Ophthalmic SuspensionDrug

    PDP-716

  • Brimonidine Tartrate Ophthalmic SolutionDrug

    Three Times Brimonidine Tartrate Ophthalmic Solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Mean Intraocular PressureTime frame: Week 12 8 AM, 10 AM and 4 PM

Locations

47 sites in 1 country. Site status is shown where the registry gives one.

  • SPARC Site 4

    Chandler, Arizona

  • SPARC Site 5

    Prescott, Arizona

  • SPARC Site 3

    Sun City, Arizona

  • SPARC Site 38

    Burbank, California

  • SPARC Site 44

    Glendale, California

  • SPARC Site 45

    Glendale, California

  • SPARC Site 43

    Mission Hills, California

  • SPARC Site 1

    Newport Beach, California

  • SPARC Site 14

    Santa Barbara, California

  • SPARC Site 47

    Torrance, California

  • SPARC Site 7

    Colorado Springs, Colorado

  • SPARC Site 11

    Coral Springs, Florida

  • SPARC Site 29

    Deerfield Beach, Florida

  • SPARC Site 34

    Fort Myers, Florida

  • SPARC Site 46

    Hollywood, Florida

  • SPARC Site 21

    Jacksonville, Florida

  • SPARC Site 35

    Miami, Florida

  • SPARC Site 27

    Miami, Florida

  • SPARC Site 10

    Miami, Florida

  • SPARC Site 16

    Miami, Florida

  • SPARC Site 19

    Miami, Florida

  • SPARC Site 25

    Miami, Florida

  • SPARC Site 41

    Pompano Beach, Florida

  • SPARC Site 18

    Tampa, Florida

  • SPARC Site 42

    Atlanta, Georgia

  • SPARC Site 2

    Morrow, Georgia

  • SPARC Site 22

    Roswell, Georgia

  • SPARC Site 12

    Chicago, Illinois

  • SPARC Site 23

    Paducah, Kentucky

  • SPARC Site 40

    Bowie, Maryland

  • SPARC Site 28

    Kansas City, Missouri

  • SPARC Site 48

    Kansas City, Missouri

  • SPARC Site 31

    St Louis, Missouri

  • SPARC Site 15

    Poughkeepsie, New York

  • SPARC Site 36

    Rochester, New York

  • SPARC Site 30

    Gastonia, North Carolina

  • SPARC Site 9

    High Point, North Carolina

  • SPARC Site 17

    Winston-Salem, North Carolina

  • SPARC Site 33

    Fargo, North Dakota

  • SPARC Site 37

    Cincinnati, Ohio

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.